Carregant...
Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
BACKGROUND: The first‐line standard treatment of non‐small cell lung cancer (NSCLC) with EGFR mutation is EGFR‐tyrosine kinase inhibitors (TKIs). However, most patients will develop acquired resistance after 9–13 months. This study investigated novel molecular mechanisms of acquired resistance to EG...
Guardat en:
| Publicat a: | Thorac Cancer |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons Australia, Ltd
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7180561/ https://ncbi.nlm.nih.gov/pubmed/32163227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13342 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|